This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

Rusfertide, developed by Protagonist Therapeutics and licensed to Takeda, is a peptide drug designed to treat polycythemia vera (PV), a blood disorder in which the body overproduces red blood cells, causing the blood to thicken — much like a highway becoming dangerously congested. It works by reducing the need for a painful and burdensome procedure called therapeutic phlebotomy, which is a regular blood-letting used to keep red blood cell levels under control, and early trial data showed it could essentially eliminate that procedure for many patients.